Trial · NCT01940887
Adverse events202
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 202
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cholelithiasis | Hepatobiliary disorders | E10030 + Bevacizumab or Aflibercept | 0 | 322 | 0 |
| serious | Cholelithiasis | Hepatobiliary disorders | Sham + Bevacizumab or Aflibercept | 1 | 320 | 1 |
| serious | Bronchitis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 1 | 322 | 1 |
| serious | Bronchitis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 2 | 320 | 2 |
| serious | Bronchopulmonary aspergillosis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 1 | 322 | 1 |
| serious | Bronchopulmonary aspergillosis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 0 | 320 | 0 |
| serious | Cellulitis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 1 | 322 | 1 |
| serious | Cellulitis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 1 | 320 | 1 |
| serious | Clostridium difficile colitis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 1 | 322 | 1 |
| serious | Clostridium difficile colitis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 0 | 320 | 0 |
| serious | Endophthalmitis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 4 | 322 | 4 |
| serious | Endophthalmitis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 1 | 320 | 1 |
| serious | Gastrointestinal infection | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 0 | 322 | 0 |
| serious | Gastrointestinal infection | Infections and infestations | Sham + Bevacizumab or Aflibercept | 1 | 320 | 1 |
| serious | Nasopharyngitis | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 1 | 322 | 1 |
| serious | Nasopharyngitis | Infections and infestations | Sham + Bevacizumab or Aflibercept | 0 | 320 | 0 |
| serious | Nosocomial infection | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 0 | 322 | 0 |
| serious | Nosocomial infection | Infections and infestations | Sham + Bevacizumab or Aflibercept | 1 | 320 | 1 |
| serious | Pneumonia | Infections and infestations | E10030 + Bevacizumab or Aflibercept | 5 | 322 | 5 |
| serious | Pneumonia | Infections and infestations | Sham + Bevacizumab or Aflibercept | 2 | 320 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01940887/events?page=5